A study of cannabidiol as treatment for severe symptoms of autism in Pediatric patients
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2019
Price : $35 *
At a glance
- Drugs Cannabidiol (Primary)
- Indications Autistic disorder
- Focus Therapeutic Use
- 07 Mar 2019 According to an INSYS Therapeutics, Inc media release, the company has received IND acceptance to study Cannabidiol in Autism in collaboration with CMCR.
- 12 Oct 2018 According to an INSYS Therapeutics, Inc media release, the company anticipates the filing of IND (investigational new drug) application for the study in the fourth quarter of 2018.
- 03 May 2018 New trial record